Evidence map›Paper›PMID 31502471›Full record

ArticleCancer control : journal of the Moffitt Cancer Center

Breast Cancer Screening Program in Lithuania: Interval Cancers and Program Sensitivity After 7 Years of Mammography Screening.

Laura Steponaviciene, Ieva Vincerzevskiene, Ruta Briediene, Vincas Urbonas, Rasa Vanseviciute-Petkeviciene, Giedre Smailyte

Abstract read
In one paragraph

Article in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Lung cancer screening in Lithuania: a cost-effectiveness analysis.Journal of comparative effectiveness research · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Laura SteponavicieneLaboratory of Cancer Epidemiology, National Cancer Institute, Vilnius, Lithuania.ORCID https://orcid.org/0000-0002-8663-675X
Ieva VincerzevskieneLaboratory of Cancer Epidemiology, National Cancer Institute, Vilnius, Lithuania.
Ruta BriedieneDepartment of Radiology, National Cancer Institute, Vilnius, Lithuania.
Vincas UrbonasLaboratory of Clinical Oncology, National Cancer Institute, Vilnius, Lithuania.ORCID https://orcid.org/0000-0002-8070-6163
Rasa Vanseviciute-PetkevicieneOutpatients Department, National Cancer Institute, Vilnius, Lithuania.ORCID https://orcid.org/0000-0001-7597-8554
Giedre SmailyteLaboratory of Cancer Epidemiology, National Cancer Institute, Vilnius, Lithuania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveAnalysis of interval cancers is critical in determining the sensitivity of screening and represents an objective measure of the quality of mammography screening program (MSP).

methodsPeriod analyzed: from 2006 to 2012. The rate of screen-detected, interval cancers and program sensitivity were measured. A comparison of screen-detected and interval cancers was performed.

resultsDuring the period of the study, 429 473 women were screened and 1297 were found to have cancer. The overall screen-detected cancer rate was 30.2 per 10 000 women screened. Four hundred thirty-one case of interval cancers have occurred during the period of the study. The interval cancer ratio (ICR) was 0.25. Overall sensitivity of MSP amounted to 75.1%. Slightly lower sensitivity was found among the youngest age-group, especially for those with lobular cancers. Interval cancers were bigger in size, more often with metastases in lymph nodes, than screen-detected cancers, but these differences were not statistically significant.

conclusionsOverall program sensitivity in Lithuania is about 75%, ICR is 0.25, and these parameters are comparable to other European countries.

Indexed as

AgedBreast NeoplasmsEarly Detection of CancerFemaleHumansLithuaniaLymph NodesMammographyMass ScreeningMiddle AgedReproducibility of ResultsSensitivity and Specificitybreast cancerinterval cancersprogram sensitivityscreening program

Identifiers

PMID31502471
PMCPMC6755864

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.